Rallybio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Rallybio kazanç ve gelirinin sırasıyla yıllık 76.4% ve 75.6% oranında artması tahmin edilirken, EPS'nin yıllık 66% oranında büyümesi bekleniyor.

Anahtar bilgiler

76.4%

Kazanç büyüme oranı

65.96%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.5%
Gelir büyüme oranı	75.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	10 Apr 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jul 10

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Jan 30

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Jul 07

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Mar 16

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:RLYB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	N/A	-30	N/A	N/A	1
12/31/2027	N/A	-26	N/A	N/A	1
12/31/2026	N/A	-26	N/A	N/A	2
3/31/2026	1	-8	-28	-28	N/A
12/31/2025	1	-9	-30	-30	N/A
9/30/2025	1	-14	-35	-35	N/A
6/30/2025	1	-42	-42	-42	N/A
3/31/2025	1	-48	-44	-44	N/A
12/31/2024	1	-58	-49	-49	N/A
9/30/2024	1	-67	-51	-51	N/A
6/30/2024	0	-74	-54	-54	N/A
3/31/2024	N/A	-76	-57	-57	N/A
12/31/2023	N/A	-75	-60	-60	N/A
9/30/2023	N/A	-71	-64	-64	N/A
6/30/2023	N/A	-71	-62	-62	N/A
3/31/2023	N/A	-69	-62	-62	N/A
12/31/2022	N/A	-67	-57	-57	N/A
9/30/2022	N/A	-63	-52	-52	N/A
6/30/2022	N/A	-55	-48	-48	N/A
3/31/2022	N/A	-48	-48	-47	N/A
12/31/2021	N/A	-47	-46	-46	N/A
9/30/2021	N/A	-45	-43	-43	N/A
6/30/2021	N/A	-42	-38	-38	N/A
3/31/2021	N/A	-36	-29	-28	N/A
12/31/2020	N/A	-26	-22	-22	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RLYB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RLYB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RLYB önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RLYB gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: RLYB gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RLYB 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/20 05:48
Gün Sonu Hisse Fiyatı	2026/05/20 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Rallybio Corporation 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jonathan Wolleben	Citizens JMP Securities, LLC
Eun Kyung Yang	Jefferies LLC
Ritu Baral	TD Cowen

Rallybio Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 24% to US$10.50

No longer forecast to breakeven

Forecast to breakeven in 2027

Consensus revenue estimates increase by 33%

Consensus EPS estimates upgraded to US$1.34 loss

Price target decreased by 19% to US$10.50

Recent updates

Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Candid Therapeutics, Inc. agreed to acquire Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Rallybio Corporation Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Announces Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Capital Market

Rallybio Corporation Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Nasdaq Transfers Rallybio Corporation Listing to Nasdaq Capital Market, Eligible for an Additional 180 Calendar Day Period to Regain Compliance with the Minimum Closing Bid Price Requirement

New major risk - Financial position

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate

Rallybio Corporation Initiates Dosing in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Price target increased by 24% to US$10.50

Rallybio Corporation to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Corporation, Annual General Meeting, May 13, 2025

New minor risk - Share price stability

No longer forecast to breakeven

Rallybio Corporation Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Requirement

Rallybio Corporation Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Forecast to breakeven in 2027

Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting

Rallybio Corporation Announces to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Corporation Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Consensus revenue estimates increase by 33%

Rallybio Corporation Announces Initiation of Phase 2 Clinical Trial of RLYB212

Consensus EPS estimates upgraded to US$1.34 loss

New minor risk - Profitability

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors